Published in J Viral Hepat on September 15, 2014
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One (2015) 0.84
Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol (2016) 0.79
Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon (2014) 0.79
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther (2016) 0.79
The payers' perspective on gene therapies. Nat Biotechnol (2015) 0.77
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One (2016) 0.75
Rethinking cost-effectiveness in the era of zero healthcare spending growth. Int J Equity Health (2016) 0.75
Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands. PLoS One (2016) 0.75
Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ (2016) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Epidemiology of hepatitis C. Hepatology (1997) 4.90
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med (1997) 2.09
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int (2011) 1.64
Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations. Eur J Gastroenterol Hepatol (2010) 1.51
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol (2010) 1.43
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
Treatment of patients with hepatitis C and cirrhosis. Hepatology (2002) 1.02
New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract (2012) 1.01
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res (2012) 1.01
Continuity of care -- a chameleon concept. J Health Serv Res Policy (2002) 0.94
Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol (2010) 0.91
Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007). Antivir Ther (2012) 0.88
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol (2013) 0.88
Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol (2013) 0.85
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis (2012) 0.82
Proteomic analysis of integrin alphaIIbbeta3 outside-in signaling reveals Src-kinase-independent phosphorylation of Dok-1 and Dok-3 leading to SHIP-1 interactions. J Thromb Haemost (2009) 0.96
Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy (2012) 0.94
Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun (2009) 0.93
Nutritional status of the Puerto Rican population: master sample survey. Am J Clin Nutr (1971) 0.87
Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther (2011) 0.85
Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat (2008) 0.83
Closure of refractory gastrocutaneous fistula using endoclipping. Endoscopy (2005) 0.82
Neuropsychiatric symptoms in elderly inpatients: a multicenter cross-sectional study. Dement Geriatr Cogn Dis Extra (2013) 0.75
[Kinds of home accidents]. G Ital Med Lav (1992) 0.75
Coronary angiography and angioplasty in a patient with an iliac artery volvolus. HSR Proc Intensive Care Cardiovasc Anesth (2010) 0.75
[Acute hepatitis in the course of cyclosporine therapy of Crohn's disease]. Presse Med (1999) 0.75